Navigation Links
Positive Phase II Study of Pacira's EXPAREL(TM) (DepoBupivacaine) in Total Knee Arthroplasty Presented at International College of Surgeons World Congress
Date:12/6/2008

New Sustained-Release Analgesic Significantly Reduces Postop Pain, Opioid Use, and Reduces Opioid Related Adverse Events Compared to Gold Standard Pain Medication

PARSIPPANY, N.J., Dec. 6 /PRNewswire/ -- A Phase II dose escalation study of a single intraoperative administration of EXPAREL(TM) (DepoBupivacaine) in patients who underwent total knee arthroplasty, or TKA, showed that the novel, sustained-release analgesic effectively and safely controlled moderate-to-severe postoperative pain for over 72 hours, it was reported today in a poster at the Biennial World Congress of the International College of Surgeons in Vienna, Austria. Commenting on the results, Kenneth W. Bramlett, MD, Orthopedic Department, West Alabama Research in Birmingham, Alabama concluded EXPAREL significantly reduced postoperative pain, decreased the use of opioids (therefore lowering associated side effects), and allowed some patients to avoid the use of opioids altogether.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070618/PACIRALOGO)

EXPAREL, a proprietary product from Pacira Pharmaceuticals, Inc., is a novel long-acting, sustained-release formulation of bupivacaine HCL, a local anesthetic widely used for treating postoperative pain.

Dr. Bramlett said, "EXPAREL effectively controlled moderate to severe pain for more than 72 hours, with better relief achieved with higher doses and a dose-dependent effect in both analgesia and reduction in opioid rescue." He pointed out the clinical importance of the study outcomes noting that EXPAREL efficacy was statistically significant against bupivacaine, the gold standard of local anesthetics, rather than simply placebo, concluding, "EXPAREL may provide safe and effective, prolonged pain relief and an opioid-sparing alternative to currently available local analgesics."


'/>"/>
SOURCE Pacira Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Kiadis Pharma Announces Positive Clinical Results for ATIR(TM) in Mismatched Bone Marrow Transplantations
2. Third Pivotal Phase 3 Study for NicOx Naproxcinod Shows Positive Efficacy, Safety and Blood Pressure Results
3. Nplate(TM) (Romiplostim) Receives Positive Opinion for Marketing Authorisation in the European Union
4. Jazz Pharmaceuticals and UCB Announce Positive Phase III Results for Sodium Oxybate (JZP-6) in Fibromyalgia
5. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
6. Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. VIA Pharmaceuticals Announces Positive Results of Phase 2 Studies of VIA-2291 in Patients With Serious Cardiovascular Disease
9. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
10. Cepheid Molecular Diagnostic Test for Positive Blood Culture Bottles Categorized Moderate Complexity by FDA
11. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  BC Technical, ... Solutions, has acquired Eclipse Systems, a Nuclear Imaging ... solutions. As part of their ongoing vision to ... an affordable rate, BC Technical continues to expand ... BC Technical to add valuable resources and knowledge ...
(Date:3/2/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today ... 2014. Total revenues were $4.3 million for the three ... months ended December 31, 2013.  Net loss was $5.9 ... as compared to a net loss of $5.1 million ... million and net loss was $22.1 million for the ...
(Date:3/2/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today reported financial ... 31, 2014. Financial highlights for the fourth quarter include revenues ... or $0.04 per share. This compares to revenues of $12.5 ... per share, for the fourth quarter of 2013. Financial highlights ... and a net loss of $68.4 million, or $0.56 per ...
Breaking Medicine Technology:BC Technical Acquires Eclipse Systems 2DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 2DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 3DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 4DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 5DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 6DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 7DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 8DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 9DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 10DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 11DURECT Corporation Announces Fourth Quarter 2014 Financial Results and Update of Programs 12Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 2Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 3Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 4Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 5Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 6Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 7Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 8Halozyme Reports Fourth Quarter And Full Year 2014 Financial Results 9
(Date:3/3/2015)... March 03, 2015 HealthCarePoint ... networking-technology corporation, announced today that it has completed ... Clinical Data Interchange Standards Consortium (CDISC). HCP will ... to standardize knowledge-based training and certifications globally. HCP’s ... and web support as well as development of ...
(Date:3/3/2015)... Salt Lake City, UT (PRWEB) March 03, 2015 ... is an innovative, user-friendly website that focuses ... wilderness therapy, therapeutic boarding schools, and addiction treatment ... Additionally, all residential interventions on the site ... assessments, anxiety, ADHD, autism spectrum disorders, severe learning ...
(Date:3/2/2015)... March 02, 2015 Calvary Hospital ... their Brooklyn Satellite in Lutheran Medical Center, with ... award must demonstrate excellence through clinical expertise as ... expected to go above and beyond to make ... with patients and their families. Award recipients are ...
(Date:3/2/2015)... Dr. David Knepp, a leading chiropractor with ... Doctors on Liens to bring his medical team’s ... personal injury victims to have access to multiple specialists ... basis. However, San Diego Chiropractic Group does ... pain management physician, massage, and acupuncture to help aid ...
(Date:3/2/2015)... 1% for the Planet , one of ... over 25 new business members at this year’s Expo West ... 1% for the Planet welcomes them and more, including Boulder ... nut butter line. , Food - how we grow ... continues to be a complex environmental issue throughout the country ...
Breaking Medicine News(10 mins):Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 2Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 3Health News:All Kinds of Therapy – New Website for Behavioral Health and Substance Abuse Treatment Launches Today 2Health News:Calvary Hospital Honors Peter Acerios, RN, with Daisy Award 2Health News:Distinguished Doctor Brings His Multi-Specialty Medical Group to Doctors on Liens in San Diego 2Health News:1% For the Planet Members Shine Light on Food as Environmental Issue at Expo West 2Health News:1% For the Planet Members Shine Light on Food as Environmental Issue at Expo West 3
... Testing for the presence of specific cancer protein ,fingerprints, ... a useful means of identifying a subgroup whose tumors ... drug erlotinib, especially when other testing methods are unavailable, ... Lung Cancer Conference in Geneva, Switzerland. Erlotinib is ...
... finds , FRIDAY, April 30 (HealthDay News) -- A shared ... spouses of kidney dialysis patients are at increased risk for ... were surprised to find that the risk of developing chronic ... as high as it is for blood relatives of these ...
... treatment decisions and political advocacy, study finds , FRIDAY, April ... than just their parents in their corner, with a new ... in the lives of kids with the developmental disorder. , ... the care of youngsters with autism. In fact, the report ...
... are known to have a higher risk of cancer, compared ... immunosuppressive drugs to prevent organ rejection. Results published today from ... to increase this cancer risk. Evaluating data from 1983 ... 481 patients over 20 years - providing the strongest evidence ...
... ... ABBY Award winners: A-Life Medical, Inc.; Specialists On Call, Inc.; and VQ OrthoCare, as ... Novasys Medical, Inc. The winners were announced at ABL Organization’s 12th Annual Innovations in ... ...
... with 2 men who had not been helped with ... Injecting a local anesthetic next to a group of ... is a fast-acting and effective way to treat combat-related ... , The 10-minute procedure, called a stellate ganglion block, ...
Cached Medicine News:Health News:Blood test may identify lung cancer patients likely to respond to erlotinib 2Health News:Why Spouses of Dialysis Patients Get Kidney Disease Too 2Health News:Grandparents Play Vital Role for Autistic Children 2Health News:Grandparents Play Vital Role for Autistic Children 3Health News:Cancer risk for kidney transplant 2Health News:ABBY Winners Announced & Honored with 2010 Innovations in Healthcare(SM) Awards 2Health News:ABBY Winners Announced & Honored with 2010 Innovations in Healthcare(SM) Awards 3Health News:Local Anesthetic May Relieve PTSD Symptoms 2
Helveston tying forceps, standard with smooth jaws. For 4-0 to 6-0 sutures....
Anis tying forcep is extra delicate with smooth jaws, curved. For 9-0 to 11-0 sutures....
Curved shafts and tips with 7 mm tying platform. Serrated handle with polished finish. Overall length 4 inches....
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Curved shafts. Overall length 3.9 inches....
Medicine Products: